var data={"title":"Tetanus immune globulin (human): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tetanus immune globulin (human): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7028?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tetanus-immune-globulin-human-drug-information\" class=\"drug drug_general\">see &quot;Tetanus immune globulin (human): Drug information&quot;</a> and <a href=\"topic.htm?path=tetanus-immune-globulin-human-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tetanus immune globulin (human): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226065\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>HyperTET S/D</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226066\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>HyperTET S/D</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2528420\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Immune Globulin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445145\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis of tetanus:</b> IM: 250 units regardless of weight or age (Bradley 2015; CDC/ACIP [Chapman 2008]; <i>Red Book</i> [AAP 2012]); may also calculate 4 units/kg; however, most experts recommend using full vial dose.   </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of tetanus:</b> IM: 3,000 to 6,000 units. Infiltration of part of the dose around the wound is recommended. Some experts recommend a lower 500 unit dose which appears to be as effective as higher doses and may cause less discomfort (Bradley 2015; <i>Red Book</i> [AAP 2012]; WHO 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2528430\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=tetanus-immune-globulin-human-drug-information\" class=\"drug drug_general\">see &quot;Tetanus immune globulin (human): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prophylaxis of tetanus: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children &lt;7 years: I.M.:  250 units regardless of weight or age (<i>Red Book</i> [AAP 2012); may also calculate 4 units/kg; however, most experts recommend using full vial dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;7 years, Adolescents, and Adults: IM: 250 units as a single dose; may be increased to 500 units if there has been a delay in initiating prophylaxis or when the wound is considered very tetanus prone</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tetanus prophylaxis in wound management</b> (CDC/ACIP [Broder 2006]): Infants, Children, Adolescents, and Adults: IM: Tetanus prophylaxis in patients with wounds should be based on if the wound is clean or contaminated and the immunization status of the patient. Wound management includes proper use of tetanus toxoid and/or tetanus immune globulin (TIG), wound cleaning, and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow-up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until &gt;10 years after the most recent dose even if they have a wound that is neither clean nor minor. See table.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Tetanus Prophylaxis Wound Management</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">History of Tetanus Immunization (Doses)</p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Clean, Minor Wounds</p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">All Other Wounds<sup>1</sup></p></th></tr></thead>\n      <tfoot>\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>Such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; wounds from crushing, tears, burns, and frostbite.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>2</sup>Tetanus toxoid in this chart refers to a tetanus toxoid containing vaccine. For children &lt;7 years old DTaP (DT, if pertussis vaccine contraindicated) is preferred to tetanus toxoid alone. For children &ge;7 years of age, Adolescents, and Adults, Td preferred to tetanus toxoid alone; Tdap may be preferred if the patient has not previously been vaccinated with Tdap.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>3</sup>Yes, if &ge;10 years since last dose.</p></td></tr>\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>4</sup>Yes, if &ge;5 years since last dose. </p></td></tr>\n        <tr>\n          <td colspan=\"5\" align=\"left\">\n            <p style=\"text-indent:0em;\">Abbreviations: <b>DT</b> = Diphtheria and Tetanus Toxoids (formulation for age &le;6 years); <b>DTaP</b> = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (formulation for age &le;6 years; Daptacel&reg;, Infanrix&reg;); <b>Td</b> = Diphtheria and Tetanus Toxoids (formulation for age &ge;7 years; Decavac&reg;, Tenivac&trade;); <b>TT</b> = Tetanus toxoid (adsorbed [formulation for age &ge;7 years]); <b>Tdap</b> = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (Adacel&reg; or Boostrix&reg; [formulations for age &ge;7 years]); <b>TIG</b> = Tetanus Immune Globulin</p></td></tr></tfoot>\n      <tbody>\n        <tr>\n          <td align=\"center\"></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Tetanus toxoid <sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">TIG</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Tetanus toxoid <sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">TIG</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Uncertain or &lt;3 doses</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Yes</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Yes</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Yes</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">3 or more doses</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No<sup>3</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No<sup>4</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of tetanus:</b> Infants, Children, Adolescents, and Adults: IM: 3,000 to 6,000 units. Infiltration of part of the dose around the wound is recommended. Some experts recommend a lower 500 unit dose which appears to be as effective as higher doses and may cause less discomfort (Bradley 2015; <i>Red Book</i> [AAP 2012]; WHO 2010).</p>\n    <p style=\"text-indent:0em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:0em;\">\n      <b>Dosing adjustment in hepatic impairment: </b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226053\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injectable, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HyperTET S/D: 250 units/mL (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226040\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2528431\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM: Administer into lateral aspect of midthigh or deltoid muscle of upper arm; not for IV administration.  Avoid gluteal region due to risk of injury to sciatic nerve; if gluteal region is used, administer only in the upper outer quadrant. When administered for treatment of tetanus, may be infiltrated locally around the wound site. Do not administer tetanus toxoid and TIG in same syringe (toxoid will be neutralized); tetanus toxoid may be administered at the same time at a separate site. To prevent syncope-related injuries, adolescents and adults should be vaccinated while seated or lying down (NCIRD/ACIP 2011).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226064\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 2&deg;C to 8&deg;C (26&deg;F to 46&deg;F). Do not use if frozen.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2528421\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prophylaxis for tetanus following injury in patients whose immunization for tetanus is incomplete or uncertain [FDA approved in pediatric patients (age not specified) and adults]</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends passive immunization with tetanus immune globulin (TIG) for the following:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons with a wound that is not clean or minor and who have received &le;2 or an unknown number of adsorbed tetanus toxoid doses (CDC/ACIP [Broder 2006]; CDC/ACIP [Kretsinger 2006]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons who are wounded in bombings or similar mass casualty events if no reliable history of completed primary vaccination with tetanus exists. In case of shortage, use should be reserved for persons &ge;60 years of age and immigrants from regions other than Europe or North America (CDC/ACIP [Chapman 2008]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226080\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Increased body temperature</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local soreness/soreness at injection site, pain at injection site, tenderness at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylactic shock, angioedema, nephrotic syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25709161\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226044\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; immediate treatment (including epinephrine 1 mg/mL) should be available. Use with caution in patients with isolated immunoglobulin A deficiency or a history of systemic hypersensitivity to human immunoglobulins.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding disorders: Use with caution in patients with thrombocytopenia or coagulation disorders; IM injections may be contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Not for intravenous administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: When used for the treatment of tetanus infection, TIG removes circulating toxin, but does not remove toxin bound to nerve endings (CDC 2012). Larger doses of TIG are needed for treatment than prophylaxis (see Dosage) (MMWR 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin testing: Skin testing should not be performed as local irritation can occur and be misinterpreted as a positive allergic reaction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300119\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226048\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12834&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Consult full interaction monograph for dose interval recommendations.  This interaction does not apply to oral Ty21a typhoid vaccine or others listed as exceptions.<b> Exceptions: </b>Influenza Virus Vaccine (Live/Attenuated); Rotavirus Vaccine; Yellow Fever Vaccine; Zoster Vaccine (Live/Attenuated).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226050\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6742397\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Tetanus immune globulin and a tetanus toxoid containing vaccine are recommended by the ACIP as part of the standard wound management to prevent tetanus in pregnant women (CDC 57[RR6], 2008; CDC 62[7], 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226043\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Provides passive immunity towards tetanus by supplying antibodies to neutralize the free form of toxins produced by <i>Clostridium tetani</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226058\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Individuals with normal IgG concentration: ~23 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: IgG concentration: IM: ~2 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323952\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Injection</b> (HyperTET S/D Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 units/mL (1): $597.64</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226061\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>BayTet (MX, PK);</li>\n      <li>Hyper-Tet (HK, KR);</li>\n      <li>Hypertet (IL, TW);</li>\n      <li>Igantet (AR, CL, MY, SG);</li>\n      <li>Ronsen Yipu (CN);</li>\n      <li>Sero-Tet (MY, PH);</li>\n      <li>Tetabulin (AT, CZ, IT, KR, PL);</li>\n      <li>Tetabulin S/D (AR);</li>\n      <li>Tetabuline (BE);</li>\n      <li>Tetagam (AT, CH, IE, PT, ZA);</li>\n      <li>Tetagam P (DE, HK, ID, PH);</li>\n      <li>Tetagam-P (GR, LK, TH);</li>\n      <li>Tetaglobulin (IN);</li>\n      <li>Tetaglobuline (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Tetanobulin (TW);</li>\n      <li>Tetanobulin S/D (DE);</li>\n      <li>Tetanogamma (BR, DO);</li>\n      <li>Tetanogamma P (MX);</li>\n      <li>Tetgam (LB);</li>\n      <li>Tetuman (NL);</li>\n      <li>Tetuman berna (HK, PE, TH, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Cantery JB, et al, eds. <i>Nelson's Pediatric Microbial Therapy</i>. 21st ed. American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2006;55(RR-3):1-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetanus-immune-globulin-human-pediatric-drug-information/abstract-text/16557217 /pubmed\" target=\"_blank\" id=\"16557217 \">16557217 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control, &ldquo;Diphtheria, Tetanus, and Pertussis: Recommendations for Vaccine Use and Other Preventive Measures,&rdquo; <i>MMWR Recomm Rep</i>, 1991, 40(RR-10):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetanus-immune-globulin-human-pediatric-drug-information/abstract-text/1865873/pubmed\" target=\"_blank\" id=\"1865873\">1865873</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. <i>Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book)</i>. Atkinson W, Wolfe S, Hamborsky J, eds.12th ed., second printing. Washington DC: Public Health Foundation, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control, &ldquo;Prevention of Pertussis, Tetanus, and Diphtheria Among Pregnant and Postpartum Women and Their Infants,  Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;  <i>MMWR Recomm Rep</i>, 2008, 57(early release):1-47. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr57e0514a1.htm?s_cid=rr57e0514a1_e%20\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr57e0514a1.htm?s_cid=rr57e0514a1_e</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control, &ldquo;Recommendations for Postexposure Interventions to Prevent Infection With Hepatitis B Virus, Hepatitis C Virus, or Human  Immunodeficiency Virus, and Tetanus in Persons Wounded During Bombings and Other Mass-Casualty Events-United States, 2008: Recommendations of the Centers for Disease Control and Prevention (CDC),&rdquo; <i>MMWR Recomm Rep</i>, 2008, 57(RR-6):1-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetanus-immune-globulin-human-pediatric-drug-information/abstract-text/18668022/pubmed\" target=\"_blank\" id=\"18668022\">18668022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012.<i> MMWR Morb Mortal Wkly Rep</i>. 2013;62(7):131-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetanus-immune-globulin-human-pediatric-drug-information/abstract-text/23425962 /pubmed\" target=\"_blank\" id=\"23425962 \">23425962 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapman LE, Sullivent EE, Grohskopf LA, et al. Recommendations for postexposure interventions to prevent infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus, and tetanus in persons wounded during bombings and other mass-casualty events--United States, 2008: recommendations of the Centers for Disease Control and Prevention (CDC). <i>MMWR Recomm Rep</i>. 2008;57(RR-6):1-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetanus-immune-globulin-human-pediatric-drug-information/abstract-text/18668022 /pubmed\" target=\"_blank\" id=\"18668022 \">18668022 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo; <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetanus-immune-globulin-human-pediatric-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. <i>MMWR Recomm Rep</i>. 2006;55(RR-17):1-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetanus-immune-globulin-human-pediatric-drug-information/abstract-text/17167397 /pubmed\" target=\"_blank\" id=\"17167397 \">17167397 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization, WHO Technical Note. Current recommendations for the treatment of tetanus during humanitarian emergencies January 2010. Available at. http://www.who.int/diseasecontrol_emergencies/who_hse_gar_dce_2010_en.pdf</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12834 Version 77.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F226065\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F226066\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F2528420\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445145\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F2528430\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F226053\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F226040\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2528431\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F226064\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2528421\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F226080\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F25709161\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F226044\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300119\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F226048\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F226050\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6742397\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F226043\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F226058\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323952\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F226061\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12834|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tetanus-immune-globulin-human-drug-information\" class=\"drug drug_general\">Tetanus immune globulin (human): Drug information</a></li><li><a href=\"topic.htm?path=tetanus-immune-globulin-human-patient-drug-information\" class=\"drug drug_patient\">Tetanus immune globulin (human): Patient drug information</a></li></ul></div></div>","javascript":null}